Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

January 23, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

Name and Address of Reporting Pers GOLDBERG MURRAY A	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) (First) (Midden of the control of the contro	3. Date of Earliest Transaction (Month/Day/Year) 01/19/2012	_X_ Officer (give title Other (specify below) SVP Finance and Admin CFO Trea			
(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
TARRYTOWN, NY 10591 (City) (State) (Zir	0	Person			

(City)	(State)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	01/19/2012		Code V $M_{\underline{(1)}}$	Amount 40,800	(D)	Price \$ 20.32	130,161	D	
Common Stock	01/19/2012		F(1)	10,424	D	\$ 79.53	119,737	D	
Common Stock	01/19/2012		F(1)	13,193	D	\$ 79.53	106,544	D	
Common Stock	01/20/2012		S <u>(1)</u>	13,567	D	\$ 77.86 (2)	92,977	D	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock	01/20/2012	S <u>(1)</u>	3,216	D	\$ 78.17 (3)	89,761	D	
Common Stock	01/20/2012	S <u>(1)</u>	400	D	\$ 79.51 (4)	89,361	D	
Common Stock						5,416	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities Acquired (Instr. 8) (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying (Instr. 3 and	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 20.32	01/19/2012		M(1)		40,800	(5)	12/18/2016	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 79.53	01/19/2012		A(1)	10,424		01/19/2012	12/18/2016	Common Stock

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

GOLDBERG MURRAY A 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

SVP Finance and Admin CFO Trea

Signatures

/s/**Murray A. 01/23/2012 Goldberg

Date

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 13,567 shares of Company stock on January 20, 2012 at prices ranging from (2) \$77.51 to \$77.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 20, 2012 at each separate price.
- Represents volume-weighted average price of sales of 3,216 shares of Company stock on January 20, 2012 at prices ranging from \$78.00 (3) to \$78.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 20, 2012 at each separate price.
- Represents volume-weighted average price of sales of 400 shares of Company stock on January 20, 2012 at prices ranging from \$79.22 to \$79.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 20, 2012 at each separate price.
- (5) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (6) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3